[Lani]

here is a quick bibliography of Dr Moasser's articles on the topic (and closely related ones):


The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.
Amin DN, Campbell MR, Moasser MM.
Semin Cell Dev Biol. 2010 Dec;21(9):944-50. Epub 2010 Sep 9.
PMID: 20816829 [PubMed - in process]
Related citations
3.
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM.
Sci Transl Med. 2010 Jan 27;2(16):16ra7.
PMID: 20371474 [PubMed - indexed for MEDLINE]
Related citations
4.
HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.
Campbell MR, Amin D, Moasser MM.
Clin Cancer Res. 2010 Mar 1;16(5):1373-83. Epub 2010 Feb 23.
PMID: 20179223 [PubMed - indexed for MEDLINE]
Related citations
5.
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM.
Clin Cancer Res. 2009 Sep 1;15(17):5569-75. Epub 2009 Aug 25.
PMID: 19706807 [PubMed - indexed for MEDLINE]Free Article
Related citations
6.
MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model.
Aliu SO, Wilmes LJ, Moasser MM, Hann BC, Li KL, Wang D, Hylton NM.
J Magn Reson Imaging. 2009 May;29(5):1071-9.
PMID: 19388114 [PubMed - indexed for MEDLINE]
Related citations


9.
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA.
Clin Cancer Res. 2008 Dec 1;14(23):7878-83.
PMID: 19047117 [PubMed - indexed for MEDLINE]Free PMC ArticleFree text
Related citations
10.
HER-2-directed, small-molecule antagonists.
Arkin M, Moasser MM.
Curr Opin Investig Drugs. 2008 Dec;9(12):1264-76. Review.
PMID: 19037833 [PubMed - indexed for MEDLINE]
Related citations
11.
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.
Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, Shokat KM, Stokoe D.
Biochem J. 2008 Oct 1;415(1):97-110.
PMID: 18498248 [PubMed - indexed for MEDLINE]Free Article
Related citations

13.
The epidermal growth factor receptor family: biology driving targeted therapeutics.
Wieduwilt MJ, Moasser MM.
Cell Mol Life Sci. 2008 May;65(10):1566-84. Review.
PMID: 18259690 [PubMed - indexed for MEDLINE]
Related citations
14.
The HER family and cancer: emerging molecular mechanisms and therapeutic targets.
Sergina NV, Moasser MM.
Trends Mol Med. 2007 Dec;13(12):527-34. Epub 2007 Nov 5. Review.
PMID: 17981505 [PubMed - indexed for MEDLINE]
Related citations
15.
Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Moasser MM, Wilmes LJ, Wong CH, Aliu S, Li KL, Wang D, Hom YK, Hann B, Hylton NM.
J Magn Reson Imaging. 2007 Dec;26(6):1618-25.
PMID: 17968965 [PubMed - indexed for MEDLINE]
Related citations

17.
Targeting HER proteins in cancer therapy and the role of the non-target HER3.
Hsieh AC, Moasser MM.
Br J Cancer. 2007 Aug 20;97(4):453-7. Epub 2007 Jul 31. Review.
PMID: 17667926 [PubMed - indexed for MEDLINE]Free PMC ArticleFree text
Related citations
18.
Targeting the function of the HER2 oncogene in human cancer therapeutics.
Moasser MM.
Oncogene. 2007 Oct 11;26(46):6577-92. Epub 2007 May 7. Review.
PMID: 17486079 [PubMed - indexed for MEDLINE]
Related citations
19.
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.
Moasser MM.
Oncogene. 2007 Oct 4;26(45):6469-87. Epub 2007 Apr 30. Review.
PMID: 17471238 [PubMed - indexed for MEDLINE]
Related citations
20.
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM.
Nature. 2007 Jan 25;445(7126):437-41. Epub 2007 Jan 7.
PMID: 17206155 [PubMed - indexed for MEDLINE]
Related citations